Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

biodesix inc - BDSX

BDSX

Close Chg Chg %
8.59 -0.26 -3.03%

Closed Market

8.33

-0.26 (3.03%)

Volume: 697.31K

Last Updated:

Jan 15, 2026, 4:00 PM EDT

Trade Now

Company Overview: biodesix inc - BDSX

BDSX Key Data

Open

$8.81

 Day Range

8.21 - 9.38

52 Week Range

3.44 - 24.51

 Market Cap

$68.34M

Shares Outstanding

7.96M

 Public Float

3.81M

Beta

0.60

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$5.37

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

3.64M

  

BDSX Performance

1 Week
 
 57.33%
 
1 Month
 
 28.40%
 
3 Months
 
 33.80%
 
1 Year
 
 -62.65%
 
5 Years
 
 -98.47%
 

BDSX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About biodesix inc - BDSX

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

BDSX At a Glance

Biodesix, Inc.
919 West Dillon Road
Louisville, Colorado 80027
Phone 1-303-417-0500 Revenue 71.32M
Industry Medical/Nursing Services Net Income -42,931,000.00
Sector Health Services 2024 Sales Growth 45.299%
Fiscal Year-end 12 / 2025 Employees 273
View SEC Filings

BDSX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.782
Price to Book Ratio 10.663
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -8.125
Enterprise Value to Sales 3.281
Total Debt to Enterprise Value 0.265

BDSX Efficiency

Revenue/Employee 261,256.41
Income Per Employee -157,256.41
Receivables Turnover 8.29
Total Asset Turnover 0.719

BDSX Liquidity

Current Ratio 2.758
Quick Ratio 2.688
Cash Ratio 1.84

BDSX Profitability

Gross Margin 70.653
Operating Margin -48.035
Pretax Margin -60.192
Net Margin -60.192
Return on Assets -43.305
Return on Equity -337.296
Return on Total Capital -51.816
Return on Invested Capital -58.378

BDSX Capital Structure

Total Debt to Total Equity 296.877
Total Debt to Total Capital 74.803
Total Debt to Total Assets 62.49
Long-Term Debt to Equity 293.332
Long-Term Debt to Total Capital 73.91
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Biodesix Inc - BDSX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
54.51M 38.21M 49.09M 71.32M
Sales Growth
+19.64% -29.89% +28.46% +45.30%
Cost of Goods Sold (COGS) incl D&A
33.08M 17.16M 15.88M 20.93M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.18M 3.60M 5.51M 5.46M
Depreciation
1.23M 1.62M 3.52M 3.45M
Amortization of Intangibles
1.95M 1.98M 1.98M 2.01M
COGS Growth
+34.86% -48.13% -7.47% +31.84%
Gross Income
21.43M 21.05M 33.21M 50.39M
Gross Income Growth
+1.90% -1.75% +57.74% +51.73%
Gross Profit Margin
+39.31% +55.10% +67.66% +70.65%
2021 2022 2023 2024 5-year trend
SG&A Expense
60.75M 71.56M 74.51M 84.65M
Research & Development
12.79M 13.10M 9.99M 9.56M
Other SG&A
47.96M 58.46M 64.52M 75.09M
SGA Growth
+40.79% +17.80% +4.12% +13.61%
Other Operating Expense
- - - -
-
Unusual Expense
(676.00K) 6.98M 1.32M 1.62M
EBIT after Unusual Expense
(38.64M) (57.48M) (42.62M) (35.88M)
Non Operating Income/Expense
(9.00K) 109.00K 6.00K 73.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.51M 8.07M 9.54M 7.12M
Interest Expense Growth
-40.72% +79.06% +18.14% -25.33%
Gross Interest Expense
4.51M 8.07M 9.54M 7.12M
Interest Capitalized
- - - -
-
Pretax Income
(43.16M) (65.45M) (52.15M) (42.93M)
Pretax Income Growth
-37.67% -51.64% +20.32% +17.67%
Pretax Margin
-79.18% -171.27% -106.23% -60.19%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(43.16M) (65.45M) (52.15M) (42.93M)
Minority Interest Expense
- - - -
-
Net Income
(43.16M) (65.45M) (52.15M) (42.93M)
Net Income Growth
-37.67% -51.64% +20.32% +17.67%
Net Margin Growth
-79.18% -171.27% -106.23% -60.19%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(43.16M) (65.45M) (52.15M) (42.93M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(43.16M) (65.45M) (52.15M) (42.93M)
EPS (Basic)
-31.5432 -31.089 -12.701 -6.6216
EPS (Basic) Growth
-33.63% +1.44% +59.15% +47.87%
Basic Shares Outstanding
1.37M 2.11M 4.11M 6.48M
EPS (Diluted)
-31.5432 -31.089 -12.701 -6.6216
EPS (Diluted) Growth
-33.63% +1.44% +59.15% +47.87%
Diluted Shares Outstanding
1.37M 2.11M 4.11M 6.48M
EBITDA
(36.14M) (46.91M) (35.79M) (28.80M)
EBITDA Growth
-88.10% -29.80% +23.70% +19.52%
EBITDA Margin
-66.30% -122.76% -72.91% -40.39%

Snapshot

Average Recommendation BUY Average Target Price 32.50
Number of Ratings 5 Current Quarters Estimate -0.803
FY Report Date 03 / 2026 Current Year's Estimate -2.428
Last Quarter’s Earnings -1.02 Median PE on CY Estimate N/A
Year Ago Earnings -5.148 Next Fiscal Year Estimate -1.33
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 5 3
Mean Estimate -0.80 -0.69 -2.43 -1.33
High Estimates -0.30 -0.24 -0.79 -0.51
Low Estimate -1.17 -1.06 -3.75 -1.84
Coefficient of Variance -45.87 -49.67 -43.75 -53.92

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Biodesix Inc - BDSX

Date Name Shares Transaction Value
May 21, 2025 Jack W. Schuler Director 20,918,174 Open market or private purchase of non-derivative security Non-derivative transaction at $0.34 per share 7,112,179.16
May 21, 2025 Jack W. Schuler Director 20,194,935 Open market or private purchase of non-derivative security Non-derivative transaction at $0.27 per share 5,452,632.45
Feb 27, 2025 Christopher Vazquez Chief Accounting Officer 45,050 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Kieran O’Kane Chief Commercial Officer 87,319 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Kieran O’Kane Chief Commercial Officer 235,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Kieran O’Kane Chief Commercial Officer 117,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Christopher Vazquez Chief Accounting Officer 90,100 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Gary Pestano Chief Development Officer 3,810 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Gary Pestano Chief Development Officer 244,400 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Gary Pestano Chief Development Officer 122,200 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Christopher Vazquez Chief Accounting Officer 39,664 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Robin Harper Cowie CFO, Sec y & Treasurer 73,398 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Robin Harper Cowie CFO, Sec y & Treasurer 235,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Robin Harper Cowie CFO, Sec y & Treasurer 117,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Scott Hutton President & CEO; Director 425,929 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Scott Hutton President & CEO; Director 775,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Scott Hutton President & CEO; Director 387,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 13, 2025 Robin Harper Cowie CFO, Sec y & Treasurer 97,070 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 13, 2025 Gary Pestano Chief Development Officer 56,510 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 13, 2025 Christopher Vazquez Chief Accounting Officer 13,112 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Biodesix Inc in the News